Paul Tudor Jones’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Paul Tudor Jones’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,000	Closed	-$18K	–	3123
2022 Q4	$18K	Hold	20,000	–	–	﹤0.01%	2271
2022 Q3	$22K	Hold	20,000	–	–	﹤0.01%	2207
2022 Q2	$25K	Hold	20,000	–	–	﹤0.01%	2005
2022 Q1	$47K	Hold	20,000	–	–	﹤0.01%	1867
2021 Q4	$62K	Hold	20,000	–	–	﹤0.01%	2258
2021 Q3	$81K	Hold	20,000	–	–	﹤0.01%	2370
2021 Q2	$97K	Hold	20,000	–	–	﹤0.01%	1533
2021 Q1	$104K	Buy	+20,000	New	+$139K	﹤0.01%	1487

Other funds holding BLPH

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paul Tudor Jones's BLPH Position: Q1 2023 in Review

Paul Tudor Jones sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q1 2023, closing a stake of 20,000 shares — an estimated $18K sold.

Paul Tudor Jones first reported a position in BLPH in Q1 2021 and held it in 8 quarters. The position peaked at $104K in Q1 2021. 19 funds tracked by Wall St. Rank hold BLPH as of Q1 2023.

Paul Tudor Jones reported no remaining Bellerophon Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Paul Tudor Jones sold 20,000 Bellerophon Therapeutics, Inc. shares in Q1 2023, an estimated $18K.
Paul Tudor Jones first reported a position in Bellerophon Therapeutics, Inc. in Q1 2021 and held it in 8 quarters.
Paul Tudor Jones's Bellerophon Therapeutics, Inc. position peaked at $104K in Q1 2021.
19 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q1 2023.

Based on Tudor Investment Corp's 13F filing for Q1 2023, filed 15 May 2023.